Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAFAEL study of psilocybin for regression of coronary atherosclerosis
2024-517902-27-00Phase 2Authorised
- Sponsor
- Psyon Therapeutics
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of psilocybin in coronary arteriosclerosis (2 arms), sponsored by Psyon Therapeutics. Primary endpoint: Change in atherosclerotic plaque volume. Planned start Nov 2024; status: authorised.
02
Drugs
psilocybin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2024-517902-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517902-27-00.